Paper36166198
B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers.
McLachlan T and 10 others. Mol Cancer Res, 2022. Cited by 48 papers, by iCite.
Cite this record
ConductScience Library. B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers. Papers, record 36166198. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36166198
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Gene Expression Regulation, Neoplastic | Major topic |
| Lymphoma, Large B-Cell, Diffuse | Major topic |
| Adult | |
| Child | |
| Humans | |
| Proto-Oncogene Proteins c-bcl-6 | |
| Immunity, Humoral | |
| Oncogenes | |
| Carcinogenesis |
Source PubMed
References102
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28368400 | Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells. | Oncogene | 2017 | https://conductscience.org/library/papers/28368400 | PubMed |
| 2 | 16819511 | STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. | Oncogene | 2007 | https://conductscience.org/library/papers/16819511 | PubMed |
| 3 | 8624821 | Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. | Immunity | 1996 | https://conductscience.org/library/papers/8624821 | PubMed |
| 4 | 12835729 | The BCL6 gene in B-cell lymphomas with 3q27 translocations is expressed mainly from the rearranged allele irrespective of the partner gene. | Leukemia | 2003 | https://conductscience.org/library/papers/12835729 | PubMed |
| 5 | 27881582 | The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/27881582 | PubMed |
| 6 | 8606720 | Non-Hodgkin's lymphoma in childhood. | N Engl J Med | 1996 | https://conductscience.org/library/papers/8606720 | PubMed |
| 7 | 29851702 | Diffuse Strong BCOR Immunoreactivity Is a Sensitive and Specific Marker for Clear Cell Sarcoma of the Kidney (CCSK) in Pediatric Renal Neoplasia. | Am J Surg Pathol | 2018 | https://conductscience.org/library/papers/29851702 | PubMed |
| 8 | 15531890 | Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. | Nat Med | 2004 | https://conductscience.org/library/papers/15531890 | PubMed |
| 9 | 29226988 | CNS high-grade neuroepithelial tumor with BCOR internal tandem duplication: a comparison with its counterparts in the kidney and soft tissue. | Brain Pathol | 2018 | https://conductscience.org/library/papers/29226988 | PubMed |
| 10 | 26919435 | New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. | Cell | 2016 | https://conductscience.org/library/papers/26919435 | PubMed |
| 11 | 21779514 | Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. | Genes Cancer | 2011 | https://conductscience.org/library/papers/21779514 | PubMed |
| 12 | 30332834 | Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance. | Int J Mol Sci | 2018 | https://conductscience.org/library/papers/30332834 | PubMed |
| 13 | 16207353 | Sequence and structural analysis of BTB domain proteins. | Genome Biol | 2005 | https://conductscience.org/library/papers/16207353 | PubMed |
| 14 | 32911532 | BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. | Blood | 2021 | https://conductscience.org/library/papers/32911532 | PubMed |
| 15 | 12692563 | Transcription-targeted DNA deamination by the AID antibody diversification enzyme. | Nature | 2003 | https://conductscience.org/library/papers/12692563 | PubMed |
| 16 | 30850381 | Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. | Blood | 2019 | https://conductscience.org/library/papers/30850381 | PubMed |
| 17 | 27482887 | Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. | J Clin Invest | 2016 | https://conductscience.org/library/papers/27482887 | PubMed |
| 18 | 24571259 | LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma. | Br J Haematol | 2014 | https://conductscience.org/library/papers/24571259 | PubMed |
| 19 | 17785200 | The endless complexity of lymphocyte differentiation and lymphomagenesis: IRF-4 downregulates BCL6 expression. | Cancer Cell | 2007 | https://conductscience.org/library/papers/17785200 | PubMed |
| 20 | 31353074 | Cortical Neurogenesis Requires Bcl6-Mediated Transcriptional Repression of Multiple Self-Renewal-Promoting Extrinsic Pathways. | Neuron | 2019 | https://conductscience.org/library/papers/31353074 | PubMed |
Cited by31
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 48 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42619836 | Surveying the Genomic Landscape of Mantle Cell Lymphoma Indicates the Importance of Multimodal Genomic and Transcriptomic Exploration. | medRxiv | 2026 | https://conductscience.org/library/papers/42619836 | PubMed |
| 42588612 | Beyond TLS Presence: A Functional Framework Integrating Maturity, Location, and Immune Context. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42588612 | PubMed |
| 42490476 | Human body single-cell atlas of three-dimensional genome organization and DNA methylation. | Science | 2026 | https://conductscience.org/library/papers/42490476 | PubMed |
| 42070207 | A lipid nanoparticle-based peptide-proteolysis-targeting chimera degrades BCL6 for diffuse large B-cell lymphoma treatment. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42070207 | PubMed |
| 41985672 | BCL6 regulates skeletal muscle mass and mitochondrial bioenergetics. | Mol Metab | 2026 | https://conductscience.org/library/papers/41985672 | PubMed |
| 41917814 | Evaluation of immunoglobulin A1/immunoglobulin A2 ratio and B cell lymphoma-6 in relation to apoptosis-associated speck-like protein in diabetic kidney disease patients. | BMC Immunol | 2026 | https://conductscience.org/library/papers/41917814 | PubMed |
| 41839945 | Splice-site mutations in POU2AF1 are associated with B-cell lymphomagenesis and therapeutic response. | Sci Rep | 2026 | https://conductscience.org/library/papers/41839945 | PubMed |
| 41726161 | Decoding the impact of nsSNP variants on BCL6 function through integrated computational analysis. | Curr Res Struct Biol | 2026 | https://conductscience.org/library/papers/41726161 | PubMed |
| 41515330 | An Update on Clinically Advanced PROTAC Degraders and Their Synthesis. | Molecules | 2025 | https://conductscience.org/library/papers/41515330 | PubMed |
| 41481115 | Proteolysis Targeting Chimeric-Based Technology in Myeloma and Lymphoma. | Mol Cancer Ther | 2026 | https://conductscience.org/library/papers/41481115 | PubMed |
| 41307210 | Rewiring the Fusion Oncoprotein EWSR1::FLI1 in Ewing Sarcoma with Bivalent Small Molecules. | J Am Chem Soc | 2025 | https://conductscience.org/library/papers/41307210 | PubMed |
| 41160353 | Conservation and diversity of genes expressed in the spines of the sea urchin. | Genes Genomics | 2026 | https://conductscience.org/library/papers/41160353 | PubMed |
| 41003230 | Candida intermedia Supplementation Enhances Immune Response and Modulates the Gut Microbiome in SARS-CoV-2 Vaccinated Mice. | J Fungi (Basel) | 2025 | https://conductscience.org/library/papers/41003230 | PubMed |
| 40821118 | Selectively targeting BCL6 using a small-molecule inhibitor is a potential therapeutic strategy for glioblastoma. | Genes Dis | 2025 | https://conductscience.org/library/papers/40821118 | PubMed |
| 40805145 | BCOR, BCORL1, and BCL6 Mutations in Pediatric Leukemias. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40805145 | PubMed |
| 40591214 | Curcumin ameliorates hepatic steatosis and insulin resistance through the JNK2/FOXO1/Bcl6 axis and regulate the intestinal flora structure. | J Physiol Biochem | 2025 | https://conductscience.org/library/papers/40591214 | PubMed |
| 40314093 | Unveiling vitamin C: A new hope in the treatment of diffuse large B‑cell lymphoma (Review). | Int J Oncol | 2025 | https://conductscience.org/library/papers/40314093 | PubMed |
| 39934754 | Clinical characteristics and genetic analysis of a patient with diffuse pulmonary lymphangiomatosis: a case report and literature review. | BMC Pulm Med | 2025 | https://conductscience.org/library/papers/39934754 | PubMed |
| 39895280 | PROTACs coupled with oligonucleotides to tackle the undruggable. | Bioanalysis | 2025 | https://conductscience.org/library/papers/39895280 | PubMed |
| 39796244 | Chemoresistance in Pancreatic Cancer: The Role of Adipose-Derived Mesenchymal Stem Cells and Key Resistance Genes. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/39796244 | PubMed |
Genes63
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36166198
GET https://conductscience.org/api/papers/v1/36166198/references?page=2